Stock listing

LS Exchange:A2ALUN SynAct Pharma AB Aktie

German listing (LS Exchange) of SynAct Pharma AB · home listing Stockholm:SYNACT

Follow SynAct Pharma AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:SYNACT

13.00 SEK 0.00 (0.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:SYNACT

Past year -38.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
12.62 – 13.16 SEKNov 20, 2026
Volume
127,189 sharesNov 20, 2026
Market cap
728.0M SEKAt the close on Nov 20, 2026 · price × 56.00M shares outstanding
52-week range
7.05 – 24.50 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
2.72M SEKMedian day 79,480 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
SynAct Pharma AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:SYNACT · Home13.00 SEK0.00 (0.0%)127,18913.0013.1612.6213.00Close on Nov 20, 2026
Frankfurt:8F8€1.138 EUR-0.006 (-0.5%)—€1.142€1.158€1.138€1.144Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:SYNACT · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
13.000.000.0%13.0013.1612.62127,189
13.00-0.58-4.3%13.3413.6012.26343,264
13.58-0.74-5.2%14.5014.5010.68820,187
14.32+1.10+8.3%13.5014.7413.50228,306
13.22-2.76-17.3%15.3815.4812.98484,269
15.98+0.92+6.1%14.8015.9814.5066,431
15.06-0.22-1.4%15.1415.3814.8678,138
15.28+0.30+2.0%14.9615.3814.4677,180
14.98-0.90-5.7%15.7415.9814.60225,549
15.88+0.18+1.1%15.4615.9215.4672,390
15.70-0.44-2.7%16.1216.5215.40221,356
16.14-0.08-0.5%16.0816.1815.18245,742
16.22-0.54-3.2%16.9816.9815.86153,318
16.76-0.72-4.1%17.4817.6816.7684,109
17.48-0.52-2.9%18.0018.1817.4094,608
18.00+0.14+0.8%17.3019.8017.30249,815
17.86+0.62+3.6%17.1018.2616.90118,908
17.24-0.16-0.9%17.4217.6016.8669,444
17.40-0.04-0.2%17.1617.5017.0047,178
17.44+0.28+1.6%17.1617.6017.0037,888
17.16+0.22+1.3%16.8017.5816.7862,065
16.94-0.06-0.4%16.9017.3016.4272,990
17.00+0.04+0.2%16.9617.7016.6634,266
16.96-0.04-0.2%16.8417.0016.2438,380
17.00-0.20-1.2%16.9417.1416.8026,865
17.20-0.02-0.1%17.0417.4816.8050,643
17.22+0.32+1.9%16.9017.3016.8049,450
16.900.000.0%16.7817.1816.5276,409
16.90-0.28-1.6%17.7617.7616.7268,887
17.18-0.04-0.2%16.9817.4416.7647,743
17.22+0.10+0.6%17.1217.7616.9840,546
17.12-0.68-3.8%17.5017.7217.0847,994
17.80+0.62+3.6%17.0417.8016.8279,638
17.18-0.32-1.8%17.8017.8016.90135,732
17.50-0.16-0.9%17.8018.0017.4268,631
17.66-0.02-0.1%17.7017.8417.3845,694
17.68+0.38+2.2%17.4017.8417.2060,968
17.30-0.16-0.9%17.5618.0617.00171,228
17.46-0.10-0.6%17.8018.0017.3655,745
17.56-0.34-1.9%17.8818.2817.5477,862
17.900.000.0%17.8818.0017.6065,810
17.90-0.06-0.3%17.9618.0417.38147,788
17.96-0.22-1.2%18.1818.2017.8069,609
18.18-0.36-1.9%18.6618.6617.8069,266
18.54+0.24+1.3%18.2018.6417.00297,291
18.30-0.32-1.7%18.4818.5018.2033,702
18.62-0.34-1.8%18.9619.0018.2861,725
18.96-0.08-0.4%19.1019.3018.48105,457
19.04-0.14-0.7%18.9019.4418.8096,715
19.18-0.48-2.4%19.4019.5018.78123,379
19.66+0.40+2.1%19.2819.7619.02190,369
19.26+1.76+10.1%17.5020.0517.20476,203
17.50+0.06+0.3%17.6217.9616.84634,397
17.44-2.48-12.4%18.7819.0017.42502,924
19.92-0.53-2.6%20.3022.4519.68949,027
20.45+0.45+2.2%20.0020.6019.68118,315
20.00+0.08+0.4%19.9420.3019.60126,760
19.92+0.48+2.5%19.4220.0019.12168,843
19.44+0.42+2.2%19.2019.7619.2098,705
19.02-0.64-3.3%19.4619.8818.9876,380
19.66+0.66+3.5%19.1819.9419.1091,565
19.00-0.84-4.2%19.9420.0018.7479,321
19.84+0.52+2.7%19.3220.0019.1469,317
19.32-2.13-9.9%20.4521.0518.90322,742
Ticker
LS Exchange:A2ALUN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

All SynAct Pharma AB news

SynAct Pharma AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 24 in all · newest Nov 18, 2026 · oldest 2026
Decks
25 decks · latest September 2026

Where SynAct Pharma AB is listed

ListingExchangeCountryCurrency
Stockholm:SYNACT · Home listingStockholmSwedenSEK
Aquis:SYNACSAquisUnited KingdomSEK
LS Exchange:A2ALUN · This pageLS ExchangeGermanyEUR
Lang & Schwarz:A2ALUNLang & SchwarzGermanyEUR
Frankfurt:8F8FrankfurtGermanyEUR
gettex:8F8gettexGermanyEUR
Aquis:SYNACSAquisUnited KingdomSEK
Munich:8F8MunichGermanyEUR
Stuttgart:8F8StuttgartGermanyEUR
Tradegate:8F8TradegateGermanyEUR

Valuation

Price/book 5.1× against a median of 2.2×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
731.1M SEK
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
SynAct Pharma AB · OMXSTO:SYNACTUS$71.29MUS$71.60Mn/an/an/a5.1×n/a0.3×n/a
Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427US$73.92MUS$52.72Mn/a1,442×n/a3.2×n/a0.0×n/a
Pentixapharm Holding AG · XETR:PTPUS$73.87MUS$69.92Mn/a1,158×n/a2.4×n/a0.0×n/a
Dimerix Limited · ASX:DXBUS$73.52MUS$62.98Mn/a21.9×n/an/a−685.3%n/an/a
Faron Pharmaceuticals Oy · LSE:FARNUS$72.99MUS$57.36Mn/an/an/a5.7×n/a1.5×n/a
Cellectis S.A. · EURONEXT:ALCLSUS$72.64M−US$9.64Mn/a−0.2×n/a1.8×−115.4%2.1×n/a
Kanaph Therapeutics Inc. · KRX:0082N0US$72.37MUS$38.83Mn/a9.3×n/a2.1×−729.8%0.0×n/a
Eastwood Bio-Medical Canada Inc · TSXV:EBMUS$72.05MUS$72.05Mn/a127×n/an/a−28.5%n/a0.56
Bioton S.A. · GPW:BIOUS$70.64MUS$86.90Mn/a1.4×6.5×0.5×−3.3%0.1×n/a
Coya Therapeutics, Inc. · NASDAQ:COYAUS$69.20MUS$33.40Mn/a7.1×n/a2.1×−643.5%0.0×1.64
MAIA Biotechnology, Inc. · AMEX:MAIAUS$68.54MUS$68.54Mn/an/an/a4.7×n/a0.0×1.62
Median of the othersUS$72.50MUS$60.17M15.6×6.5×2.2×−379.4%0.0×1.62

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
39.40 SEK · Analysts' mean
EPS, year to Dec 2026
-1.68 · 1 analyst

Team and board

Officers

OfficerRole
Jeppe ØvlesenChief Executive Officer
Ann Kristin LedChief Financial Officer
Thomas BoesenChief Operating Officer
Mads BjerregaardChief Business Officer
Thomas JonassenChief Scientific Officer

Board

DirectorRole
Anders KronborgChairman of the Board
Jeppe Ragnar AndersenBoard Member
Sten ScheibyeBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 3, 2026−1.6%
Q2 2026Aug 20, 2026−7.5%
Q1 2026May 28, 2026+9.3%
Q4 2025Feb 19, 2026+3.5%
Q3 2025Oct 30, 2025+13.6%
Q2 2025Aug 20, 2025−1.5%
Q1 2025May 27, 2025 · Before open−18.6%
Q4 2024Feb 18, 2025 · Before open+3.6%
Q3 2024Oct 30, 2024−1.5%
Q2 2024Aug 20, 2024−10.4%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 24, 2024 · Before open−3.4%
Q4 2023Feb 23, 2024 · Before open−6.1%
Q3 2023Oct 24, 2023 · Before open−2.3%
Q2 2023Aug 4, 2023 · Before open+5.3%
Q1 2023May 5, 2023 · Before open+0.4%
Q4 2022Feb 17, 2023 · Before open0.0%
Q3 2022Nov 4, 2022 · Before open−8.3%
Q2 2022Aug 5, 2022 · Before open−3.0%
Q1 2022May 30, 2022 · Before open
Q4 2021Feb 11, 2022 · Before open

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck26 slidesSeptember 2026
Investor Presentation (April 2026)Investor deck28 slidesApril 2026
Investor Presentation (February 2026)Investor deck27 slidesFebruary 2026
Investor Presentation (2025)Investor deck18 slides2025
Redeye Theme: Autoimmune and inflammatory disease (October 2023)Conference13 slidesOct 3, 2023
Corporate Update (September 2023)Corporate update11 slidesSep 13, 2023
Q2 2023 Earnings PresentationEarnings19 slidesAug 4, 2023
BIO Boston June 2023Conference18 slidesJune 2023
Investor Presentation (March 2023)Investor deck45 slidesMarch 2023
Investor Presentation (August 2022)Investor deck37 slidesAugust 2022
All 25 decks
DeckKindSlidesDate
ABG (May 2022)Conference46 slidesMay 19, 2022
Investor Presentation (March 2022)Investor deck36 slidesMarch 2022
Investor Presentation (February 2022)Investor deck36 slidesFebruary 2022
Investor Presentation (December 2021)Investor deck37 slidesDec 7, 2021
Investor Presentation (December 2021)Investor deck18 slidesDec 2, 2021
Kempen Life Sciences Conference 2021Conference30 slidesMay 2021
Investor Presentation (February 2021)Investor deck37 slidesFebruary 2021
Investor Presentation (October 2020)Investor deck27 slidesOctober 2020
Investor Presentation (May 2018)Investor deck15 slidesMay 3, 2018
Sedermeradagen Malmö 2018Conference17 slidesMay 2018
Sedermera Dagen, Copenhagen 2018Conference15 slidesMar 13, 2018
Investor Presentation (March 2017)Investor deck17 slidesMarch 2017
Investor Presentation (November 2016)Investor deck19 slidesNovember 2016
IPO Roadshow (May 2016)IPO roadshow22 slidesMay 2016
Investor Presentation (March 2016)Investor deck19 slidesMarch 2016

Open Decks

Financings

RaiseDateIn US dollars
Convertibles of series 2026/2027:2
Closed: SEK 100M raised
Buyers: Fenja Capital II A/S (second tranche of SEK 50 million)
Use of proceeds: Strengthen financial position and support continued clinical development activities and strategic priorities
Nov 18, 2026
Private placement of new shares
Closed: SEK 51.91M raised · SEK 18 a share · Navia Corporate Finance AB
Dealers: Navia Corporate Finance AB (lead)
Buyers: Hunter Capital (major shareholder that has expressed interest in participating); Johannes Schildt (major shareholder who has expressed interest in participating)
Use of proceeds: Increased financial flexibility and extending the cash runway to support post-data partnering discussions
Mar 2, 2026US$5.67M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in SEK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000000
Cost of revenue617.0K778.0K1.06M88.0K338.5K303.6K252.0K190.4K
Gross profit00000-338.5K-303.6K-252.0K-190.4K
Research and development85.6M49.3M105.1M70.1M60.5M22.8M15.2K21.8M
Selling, general and administrative31.5M40.5M33.9M35.6M16.2M8.81M24.2M28.1M17.9M
Operating income-116.5M-90.0M-224.5M-105.7M-76.7M-31.3M-24.8M-28.4M-18.2M-17.0M
Depreciation and amortization628.0K614.0K75.3M1.02M88.0K381.1K338.5K303.6K252.0K190.4K
EBITDA-115.9M-89.4M-149.2M-104.7M-76.6M-30.9M-24.5M-28.1M-17.9M-16.8M
Interest expense3.87M2.96M830.0K1.42M110.0K39.0K2.39M146.7K155.4K
Income before tax-119.0M-90.8M-224.3M-107.1M-76.8M-31.3M-27.1M-28.2M-18.0M-17.0M
Income tax-8.16M-8.42M-8.47M-7.86M-7.50M-4.75M-3.15M-4.80M-2.64M-1.54M
Net income-110.8M-82.4M-215.8M-99.2M-69.3M-26.6M-24.0M-23.4M-15.4M-15.5M
Earnings per share, basic-2.17-2.08-6.64-3.60-2.68-1.23-1.62-1.70-1.24-1.30
Earnings per share, diluted-2.17-2.08-6.64-3.60-2.68

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents53.4M61.2M62.4M108.2M24.0M14.5M3.56M7.12M10.2M26.6M
Short-term investments93.0K180.0K-208.0K
Receivables13.4M5.96M12.4M14.7M10.7M6.46M4.90M6.02M3.87M2.92M
Inventory-12.4M246.0K321.0K-22.2K-6.02M-3.87M-2.92M
Current assets71.3M94.0M75.1M140.2M34.9M21.3M8.45M13.1M14.1M29.5M
Property, plant and equipment2.10M3.18M
Goodwill0000
Total assets220.5M270.5M228.0M142.6M38.4M21.6M23.8M14.0M15.2M30.6M
Accounts payable9.49M17.3M9.67M4.72M4.25M2.77M5.46M3.23M1.78M3.16M
Current liabilities21.5M28.5M24.9M15.0M15.4M5.72M10.3M3.72M2.31M3.49M
Total debt1.81M1.88M637.0K2.06M3.09M
Total liabilities50.2M56.4M51.8M16.1M17.5M5.72M10.3M3.72M2.31M3.49M
Shareholders' equity170.3M214.2M176.2M126.5M20.9M15.9M13.5M10.3M12.9M27.1M
Shares outstanding51.1M39.5M32.5M27.6M26.0M21.7M14.8M13.8M12.4M11.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-97.3M-89.2M-100.2M-117.6M-65.0M-33.2M-16.1M-24.2M-17.2M-14.7M
Capital spending00000-33.2M-499.0K0-264.5K-903.0K
Free cash flow-97.3M-89.2M-100.2M-117.6M-65.0M-33.2M-16.6M-24.2M-17.5M-15.6M
Cash from investing00370.0K27.0K-6.00K-93.0K-499.0K-93.0K-264.5K-996.1K
Cash from financing90.5M87.4M54.0M200.7M74.3M44.7M13.0M20.8M950.9K42.1M
Change in cash-6.87M-1.79M-45.8M83.2M9.32M11.0M-3.56M-3.09M-16.4M25.8M

Open Financials

Cap table

Built by 6ix from SynAct Pharma AB’s releases · as of Nov 18, 2026

Common shares
55,998,270
Fully diluted
55,998,270

Fully diluted

LineShares
Common shares55,998,270

Share count over time

CountShares
Nov 22, 202655,998,270

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) Portfolio Europe ETF1,027US$2,234Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Quantass ApS
Closely associated with Jeppe Øvlesen (Chief Executive Officer (CEO)/Managing Directory)
Buy20,313SEK 14.25SEK 289KNov 16, 2026
TJ Biotech Holding ApS
Closely associated with Thomas Jonassen (Other senior executive)
Sale350,000SEK 17.80SEK 6.23MSep 2, 2026
Quantass ApS
Closely associated with Jeppe Øvlesen (Chief Executive Officer (CEO)/Managing Directory)
Sale150,000SEK 17.80SEK 2.67MSep 2, 2026
Anders Kronborg
Chairman of the Board of Directors
Buy2,750SEK 18.12SEK 49,830Mar 10, 2026
Quantass ApS
Closely associated with Jeppe Øvli Øvlesen (Chief Executive Officer (CEO)/Managing Directory)
Buy7,900SEK 17.99SEK 142KMar 5, 2026
Mads Liebach Bjerregaard
Other member of the company's administrative, management or supervisory body
Buy1,500SEK 17.92SEK 26,880Mar 5, 2026
Boesen Biotech ApS
Closely associated with Thomas Boesen (Other member of the company's administrative, management or supervisory body)
Buy2,700SEK 17.90SEK 48,330Mar 3, 2026
Boesen Biotech ApS
Closely associated with Thomas Boesen (Other member of the company's administrative, management or supervisory body)
Buy2,750SEK 17.92SEK 49,280Mar 3, 2026
TJ Biotech Holding ApS
Closely associated with Thomas Jonassen (Other senior executive)
Buy3,529SEK 20.45SEK 72,168Dec 19, 2025
Anders Kronborg
Chairman of the Board of Directors
Buy3,470SEK 20.84SEK 72,301Dec 19, 2025
All 12 trades
TradeTradeSharesPriceValueDate
Mads Liebach Bjerregaard
Other member of the company's administrative, management or supervisory body
Buy1,500SEK 20.35SEK 30,525Dec 17, 2025
Quantass ApS
Chief Executive Officer (CEO)/Managing Directory
Buy3,529SEK 20.24SEK 71,429Dec 17, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anders KronborgChairman of the Board · Since at least May 7, 2026
Ann Kristin LedChief Financial Officer · Since Feb 24, 2026
Jeppe ØvlesenChief Executive Officer · Since at least Sep 22, 2026
Jeppe Ragnar AndersenBoard Member · Since at least May 7, 2026
Mads BjerregaardChief Business Officer · Since at least Sep 22, 2026
Sten ScheibyeBoard Member · Since at least May 7, 2026
Sten SörensenDirector · Until Nov 16, 2026 · Past
Thomas BoesenChief Operating Officer · Since at least Aug 5, 2026
Thomas JonassenChief Scientific Officer · Since at least Sep 16, 2026

Open People

Log in to ask 6ix AI your own questions about SynAct Pharma AB.